NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.
Google Ventures led the round with Foundation Medical Partners also a new investor. Founding investors North Bridge Venture Partners and General Catalyst Partners also participated in the round.
The funding will be used to support Lexington, Mass.-based SynapDx as it develops a blood-based diagnostic test for autism spectrum disorder. The test is designed to help clinicians identify children with autism earlier than can be currently diagnosed.
In conjunction with the financing, Google's Andrew Conrad was appointed to SynapDx's board. Conrad was the chief scientific officer of Laboratory Corporation of America and co-founder of its National Genetics Institute.
In February, LabCorp made a $2 million investment into SynapDx. SynapDx raised $6 million in a Series A1 financing round in December.